RMBS, Rambus Inc.
** RMBS reported that it has signed a patent license agreement with NVIDIA.
The agreement covers the use of RMBS patented innovations in a broad range of integrated circuit products offered by NVIDIA. In addition, the two companies have settled all outstanding claims, including resolution of past use of RMBS' patented innovations. The term of this agreement is five years; other details are confidential.
RMBS is one of the world's premier technology licensing companies. As a company of inventors, RMBS focuses on the development of technologies that enrich the end-user experience of electronic systems.
More about RMBS at www.rambus.com.
ASTC, Astrotech Corporation
** ASTC's subsidiary Astrogenetix Corporation reported that it has entered into a Space Act Agreement (SAA) with NASA, (National Aeronautics and Space Administration).
This SAA commits to providing the critical resources needed to continue utilizing the International Space Station and to further the development of important on-orbit microgravity vaccines and therapeutic drug experiments.
ASTC's subsidiary Astrogenetix entered into a similar SAA in 2009 resulting in 12 successful missions on the Space Shuttle that led to the discovery of potential vaccine targets for both salmonella and MRSA. This experience clearly identified that the most important part of the discovery process is the repeated frequency of access to microgravity. The new SAA reflects this important priority and NASA has committed to provide a minimum of 28 missions between 2013 and 2016.
ASTC's subsidiary Astrogenetix Corp. is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.
ASTC is one of the first space commerce companies and remains a strong entrepreneurial force in the aerospace industry. ASTC is leader in identifying, developing and marketing space technology for commercial use.
More about ASTC at www.astrotechcorp.com
OXBT, Oxygen Biotherapeutics Inc.
** OXBT and Aurum Biosciences Ltd. of Glasgow, Scotland, reported that they have signed a long-term agreement to develop a better tool for defining the extent of injury in acute ischemic stroke and for treating this emergency in the important early hours after the attack.
At the center of both efforts is OXBT's proprietary, perfluorocarbon-based Oxycyte emulsion, which is known for delivering large amounts of oxygen to the brain. The key to the diagnostic work lies in Aurum's proprietary GOLD (Glasgow Oxygen Level-Dependent) Magnetic Resonance Imaging (MRI) technology, which has already shown great promise in mapping potentially salvageable tissue in the brain after stroke in the brain.
An ischemic stroke occurs when a blood vessel that carries oxygen and nutrients to a particular region of the brain is blocked by a clot. Once this event happens, the affected part of the brain cannot get the oxygen it needs and, therefore, begins to die.
The objective of all stroke treatments is to salvage as much of the surrounding ischemic penumbra as possible, the region of potentially viable tissue with critically low blood flow and oxygen supply. This could result in improved functional capacity in the stroke patient.
OXBT will supply Oxycyte and provide scientific expertise to Aurum for the preclinical studies that have already begun and for the clinical trials in stroke that are expected to follow. Funding of around [Pounds]240K for the project was recently secured in Scotland.
Oxycyte is a perfluorocarbon-based emulsion designed to enhance oxygen delivery to ischemic tissues that have been damaged by disease or trauma. Oxycyte molecules are approximately 50 times smaller than red blood cells allowing them to flow into small capillaries and around damaged tissue.This feature and other physical properties of Oxycyte enable it to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way.
OXBT is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. OXBT has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product that is being formulated for both intravenous and topical delivery.
More about OXBT at www.oxybiomed.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.